Table 1.
Patient demographics and clinical characteristics
| Characteristic | No. of patients (= 29) | % |
|---|---|---|
| Age (years) | ||
| Median | 59 | |
| Range | 31–75 | |
| Gender | ||
| Male | 19 | 66 |
| Female | 10 | 34 |
| Race | ||
| White | 22 | 76 |
| Black | 3 | 10 |
| Hispanic | 3 | 10 |
| Asian | 1 | 4 |
| Performance status (ECOG) | ||
| 0 | 21 | 72 |
| 1 | 8 | 28 |
| Location of primary tumor | ||
| Small intestine | 14 | 49 |
| Pancreas | 6 | 21 |
| Rectum | 2 | 7 |
| Appendix | 1 | 3 |
| Lung | 1 | 3 |
| Thymus | 1 | 3 |
| Unknown | 4 | 14 |
| Tumor grade | ||
| Low grade | 13 | 45 |
| Intermediate grade | 16 | 55 |
| Elevated baseline chromogranin A (> ULN) | ||
| Yes | 18 | 62 |
| No | 11 | 38 |
| Baseline chromogranin A (nl < 15 ng/ml) | ||
| Median | 21 | |
| Mean | 236 | |
| Range | 1–2600 | |
| Elevated baseline 5-HIAA | ||
| Yes | 9 | 31 |
| No | 13 | 45 |
| Unknown | 7 | 24 |
| Liver involvement (%) | ||
| 0 | 2 | 7 |
| <10 | 12 | 41 |
| ≥ 10 | 15 | 52 |
| Octreoscan positivity | ||
| No | 5 | 17 |
| Yes | 21 | 73 |
| Unspecified | 3 | 10 |